Dose optimization of an adjuvanted peptide-based personalized neoantigen melanoma vaccine
Fig 4
Tumor diameter on day 200 as function of constant peptide concentration on each vaccination day.
Vertical lines correspond to the lower and upper bounds set for this dose optimization study for the amount of peptides as the log-folds of the clinical trial dose. The red and green areas indicate tumor growth and reduction from the initial tumor size, respectively.